• Career and professional development for young oncologists

  Mair, M. J.; Cardone, C.; Connolly, L.; Kfoury, M.; Lambertini, M.; Lim, Kok Haw Jonathan; Mariamidze, E.; Matikas, A.; Pihlak, R.; Punie, K.; et al. (2022)

  Young oncologists around the globe face many challenges when it comes to their career and professional development. Aspects such as time management, work-life balance, career progression, and educational opportunities are only some of them. Professional societies have identified these challenges in this professional group and have designed programs to tackle them specifically. The importance of this strategy cannot be overstated, as young oncologists, defined by most societies as oncologists under 40 years of age, compose almost 50% of the oncology workforce. On the other hand, recent surveys have shown that many young oncologists are considering alternative career paths due to burnout issues aggravated by the COVID-19 pandemic, on top of all other challenges. The virtual setting that has been forcedly introduced into our professional life has shortened distances between professionals and might have contributed to more accessible access to information and opportunities that some young oncologists could not profit from due to their traveling constraints. On the other hand, this virtual setting has shown us the asymmetries in opportunities for these professionals. Knowledgeable of all this, we summarize in this article some of the career and professional development offer available to all young oncologists, which we consider could help them deal with current and future challenges.
• Health-related quality of life (HRQoL) in patients (pts) with progressive, poorly differentiated, extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC) enrolled in NET-02: A phase II trial of liposomal irinotecan (nal-IRI)/5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy

  Craig, Z.; Swain, J.; Sharma, R.; Faluyi, O. O.; Wadsley, J.; Morgan, C.; Wall, L. R.; Chau, I.; Reed, N. S.; Sarker, D.; et al. (2022)
• Targeting the cell-cycle effects of tumor treating fields (ttfields) to increase its efficacy

  Slangen, P.; Elbakary, B.; Van Mil, L.; De Gooijer, M.; Krenning, L.; Van den Broek, B.; Mertz, M.; Van Tellingen, O.; Borst, Gerben R; The Netherlands Cancer Institute, Amsterdam, Netherlands (2022)
• Rapid early progression (Rep) of glioblastoma is an independent negative prognostic factor: results from a systematic review and meta-analysis

  Waqar, M.; Roncaroli, F.; Lehrer, E.; Palmer, J.; Villanueva-Meyer, J.; Braunstein, S.; Hall, E.; Aznar, Marianne Camille; Hamer, P. D. W.; D'Urso, P.; et al. (2022)
• The preoperative brain irradiation in glioblastoma (Pobig) Study: a novel treatment paradigm to improve outcomes?

  Borst, Gerben R; Waqar, M.; McBain, Catherine A; Beasley, William J; Golby, Christopher; Hamerlik, P.; Karabatsou, T.; Bailey, M.; D'Urso, P.; Djoukhadar, I.; et al. (2022)

View more